Pathway Genomics Corporation to Launch Next-Generation Sequencing (NGS) Comprehensive Cancer Panel Including BRCA1 and BRCA2
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics, a genetic testing laboratory on the forefront of bringing physicians a broad genetic testing portfolio covering a wide range of diseases, announces the pending launch of its inherited cancer panel with BRCA1 and BRCA2. Pathway Genomics’ Hereditary Cancer DNA InsightSM test utilizes next-generation sequencing (NGS) technology and will analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others. The company notes that it intends to introduce all their cancer panels in August 2013.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics, a genetic testing laboratory on the forefront of bringing physicians a broad genetic testing portfolio covering a wide range of diseases, announces the pending launch of its inherited cancer panel with BRCA1 and BRCA2. Pathway Genomics’ Hereditary Cancer DNA InsightSM test utilizes next-generation sequencing (NGS) technology and will analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others. The company notes that it intends to introduce all their cancer panels in August 2013.
Help employers find you! Check out all the jobs and post your resume.